Dr. Lal PathLabs Ltd.’s fourth quarter profit increased, beating analysts' estimates.
The diagnostic and healthcare testing services provider’s net profit rose 83% year-on-year to Rs 154.80 crore in the quarter ended March 31, 2025, according to its exchange filing. That compares with the Rs 99.5-crore consensus estimate of analysts tracked by Bloomberg.
Dr. Lal PathLabs Q4 FY25 Highlights (YoY)
Revenue up 10.5% at Rs 602.60 crore versus Rs 545.40 crore (Bloomberg estimate: Rs 604.2 crore).
Ebitda up 17% at Rs 169 crore versus Rs 144.70 crore (Bloomberg estimate: Rs 158.9 crore).
Ebitda margin at 28% versus 26.5% (Bloomberg estimate: 26.3%).
Net profit up 83% at Rs 154.80 crore versus Rs 84.50 crore (Bloomberg estimate: 99.5 crore).
Shares of Dr. Lal PathLabs were trading 0.36% higher, as compared with a 0.62% decline in the benchmark Nifty 50.
(This is a developing story).
RECOMMENDED FOR YOU
US Stock Markets Today: S&P 500, Dow Jones Rise Amid Progress In Trade Negotiations
Jun 30, 2025
US Stocks Rise And Yields Fall On Jerome Powell’s Remarks: Markets Wrap
Jun 24, 2025
US Stocks Rise As Soft Inflation Sinks Bond Yields: Markets Wrap
Jun 12, 2025
Dr. Reddy's Share Price Gains Following Q4 Profit Beat
May 12, 2025
POPULAR